A Phase 2 interventional study of ORMD-0801 (qd) and ORMD-0801 (bid) in Type 2 Diabetes Mellitus, sponsored by Oramed, Ltd.. Completed at 1 site in United States. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-07-12.
Sponsored by Oramed, Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.
Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,216th largest by enrollment of the 2,957 interventional ones that give a count, is one of 103 that started in 2016, is one of 391 in phase 2, and was the 1,876th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
University of Minnesota · Sites in United States
Ages 30–75
Pfizer · Sites in United States
Ages 18+
Rahul Sachdeva · Sites in United States
Ages 18+ · Healthy volunteers
Amgen · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,304 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 423 · Phase 2 464 · Phase 3 613 · Phase 4 300
First in 1976; this study’s year is marked. 103 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 90 across the 2,957 interventional studies, 128 across the 336 observational. Of the 2,648 that completed or were terminated, 1,165 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
1,486 of 3,304 have an industry lead sponsor. The 10 most frequent:
Oramed, Ltd. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Oramed, Ltd. has 9 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
187 of the studies in Diabetes Mellitus, Type 2 with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06731075Phase 3Oramed, Ltd.A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus. | 2027-04-25 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Add all 187 to your calendar (.ics) → With an account.
Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a four-way crossover (non-parallel) study with each subject receiving three of the four arms. The study will enroll approximately 30 adult subjects with T2DM from age 20 to 75 inclusive.
Following a 7-10 day Screening period, eligible subjects will enter a 3-day single-blind placebo run-in. On Day 4, each subject will be randomized to a treatment sequence that will include three treatment assignments for each of three treatment Periods according to the randomization scheme.
Following the screening, eligible subjects entered a 3-day, single-blind placebo run-in. On Day 4, each subject was randomized to a treatment sequence that included three treatment assignments for each of three treatment Periods according to the randomization scheme.
Pre-assignment Details The number of participants receiving each Intervention, in each Period, is reported.
Subjects received the randomized treatment from Day 4 through Day 8. There was a 24-hour single-blind placebo washout on Day 9. Each subject received placebo for one of the three treatment periods. Each subject also received 1 of the 3 active doses randomly in each of the two other treatment periods respectively. The dosing order is random.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Females who are not of childbearing potential are defined as:
i. (defined as at least 12 months with no menses in women ≥45 years of age) ii. Has had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; OR iii. Has a congenital or acquired condition that prevents childbearing.
Females of childbearing potential agree to avoid becoming pregnant while receiving study treatment and for 14 days after the last dose of study treatment by complying with one of the following:
i. practice abstinence† from heterosexual activity OR ii. Use (or have her partner use) acceptable during heterosexual activity.
Exclusion Criteria:
Presence or history of cancer within the past 5 years of Screening, with the exception of adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer.
Laboratory abnormalities at Screening including:
Use of the following medications:
Any clinically significant abnormality at Screening or cardiovascular disease. Clinically significant cardiovascular disease will include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (fish oil)
Other: Placebo
Dose 1 ORMD-0801 (qd)
Drug: ORMD-0801 (qd)
Dose 2 ORMD-0801 (bid)
Drug: ORMD-0801 (bid)
Dose 3 ORMD-0801 (tid)
Drug: ORMD-0801 (tid)
Dose 1 = ORMD-0801 (qd)
Also known as: Oral Insulin
Dose 2 = ORMD-0801 (bid)
Also known as: Oral Insulin
Dose 3 = ORMD-0801 (tid)
Also known as: Oral Insulin
fish oil placebo
Also known as: fish oil
Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM)
Measure the change in Glucose (mg/dL) by 24 hour CGM between Day3 and Day8 (Change in mg/dL between run-in and Day 5 of Active treatment)
Time frame: Day 3 (run-in) and Day 8 (Day 5 of Active treatment)
Calculate the C-peptide Ratio for Single and Multiple Doses of ORMD-0801 vs Placebo.
For each dose, calculate the ratio of the C-Peptide measurement area-under-the-curve (ng-hr/mL) Day 8 to the C-peptide measurement area-under-the-curve (ng-hr/mL) Day 3. This ratio is called the C-peptide Ratio.
Time frame: Day 3 and Day 8
The Number Hypoglycemic Events for Single and Multiple Doses of ORMD-0801 vs Placebo
The number of safety parameter hypoglycemic events for single and multiple doses of ORMD-0801 vs placebo.
Time frame: Day 3 through Day 8 of treatment
Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose
Calculate the difference between pre-treatment (Day 3) and end of treatment (Day 8) mean daytime CGM glucose for single and multiple doses of ORMD-0801 vs placebo.
Time frame: Day 3 and Day 8 (two timepoints)
Following the screening, eligible subjects entered a 3-day, single-blind placebo run-in. On Day 4, each subject was randomized to a treatment sequence for each of three treatment periods, each period was either placebo or 1 of the 3 treatments). All subjects received placebo and only 2 of the 3 treatments.
| Milestone | Placebo | Dose1 | Dose2 | Dose 3 |
|---|---|---|---|---|
| Started | 11 | 6 | 8 | 7 |
| Completed | 11 | 6 | 7 | 7 |
| Not completed | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Milestone | Placebo | Dose1 | Dose2 | Dose 3 |
|---|---|---|---|---|
| Started | 11 | 6 | 8 | 6 |
| Completed | 11 | 6 | 8 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Dose1 | Dose2 | Dose 3 |
|---|---|---|---|---|
| Started | 9 | 8 | 6 | 8 |
| Completed | 9 | 8 | 6 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
Measure the change in Glucose (mg/dL) by 24 hour CGM between Day3 and Day8 (Change in mg/dL between run-in and Day 5 of Active treatment)
| mg/dL | Placebo | Dose 1 | Dose 2 | Dose 3 |
|---|---|---|---|---|
| Change in Glucose Levels Between Pre-treatment and End of Treatment as Measured by 24-hour Continuous Glucose Monitoring (CGM) | -4.94 ± 4.418 | -10.00 ± 7.236 | -1.21 ± 7.397 | -11.42 ± 8.451 |
For each dose, calculate the ratio of the C-Peptide measurement area-under-the-curve (ng-hr/mL) Day 8 to the C-peptide measurement area-under-the-curve (ng-hr/mL) Day 3. This ratio is called the C-peptide Ratio.
| ratio | Placebo | Dose 1 | Dose 2 | Dose 3 |
|---|---|---|---|---|
| Calculate the C-peptide Ratio for Single and Multiple Doses of ORMD-0801 vs Placebo. | 0.97 ± 0.034 | 1.01 ± 0.056 | 1.03 ± 0.047 | 0.93 ± 0.051 |
The number of safety parameter hypoglycemic events for single and multiple doses of ORMD-0801 vs placebo.
| number of hypoglycemic events | Placebo | Dose 1 | Dose 2 | Dose 3 |
|---|---|---|---|---|
| The Number Hypoglycemic Events for Single and Multiple Doses of ORMD-0801 vs Placebo | 3 | 2 | 4 | 5 |
Calculate the difference between pre-treatment (Day 3) and end of treatment (Day 8) mean daytime CGM glucose for single and multiple doses of ORMD-0801 vs placebo.
| mg/dL | Placebo | Dose 1 | Dose 2 | Dose 3 |
|---|---|---|---|---|
| Calculate the Difference Between Values of Pre-treatment and End-of-treatment Mean Daytime CGM Glucose | -4.11 ± 5.080 | -13.96 ± 7.775 | 1.13 ± 7.772 | -16.78 ± 8.613 |
Collected over One Year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/31 (0%) | 0/31 (0%) | 12/31 (38.7%) |
| Dose 1 | 0/20 (0%) | 0/20 (0%) | 7/20 (35%) |
| Dose 2 | 0/21 (0%) | 0/21 (0%) | 11/21 (52.4%) |
| Dose 3 | 0/21 (0%) | 0/20 (0%) | 3/20 (15%) |
| Event | Placebo | Dose 1 | Dose 2 | Dose 3 |
|---|---|---|---|---|
| Metabolism and Nutrional DisordersMetabolism and nutrition disorders | 7/31 | 5/20 | 6/21 | 2/20 |
| HypoglycemiaMetabolism and nutrition disorders | 2/31 | 1/20 | 4/21 | 1/20 |
| Gastrointestinal disordersGastrointestinal disorders | 3/31 | 1/20 | 2/21 | 0/20 |
| Nervous System DisordersNervous system disorders | 1/31 | 0/20 | 2/21 | 0/20 |
| Eye DisordersEye disorders | 0/31 | 0/20 | 0/21 | 1/20 |
| Muskuloskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 1/31 | 1/20 | 0/21 | 0/20 |
| Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 0/31 | 0/20 | 1/21 | 0/20 |
ITT Population
| Age, Continuous(years) | Placebo | ORMD-0801 qd | ORMD-0801 Bid | ORMD-0801 Tid | Total |
|---|---|---|---|---|---|
| Mean | 57.27 ± 7.00 | 57.17 ± 11.37 | 59.5 ± 7.03 | 58.71 ± 7.54 | 57.72 ± 7.77 |
| Sex: Female, Male(Participants) | Placebo | ORMD-0801 qd | ORMD-0801 Bid | ORMD-0801 Tid | Total |
|---|---|---|---|---|---|
| Female | 3 | 5 | 1 | 3 | 12 |
| Male | 8 | 1 | 6 | 4 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | ORMD-0801 qd | ORMD-0801 Bid | ORMD-0801 Tid | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 4 | 6 | 17 |
| Not Hispanic or Latino | 7 | 3 | 3 | 1 | 14 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | ORMD-0801 qd | ORMD-0801 Bid | ORMD-0801 Tid | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 1 | 0 | 4 |
| White | 9 | 5 | 5 | 6 | 25 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Child-Bearing Status(Participants) | Placebo | ORMD-0801 qd | ORMD-0801 Bid | ORMD-0801 Tid | Total |
|---|---|---|---|---|---|
| Not Applicable (Male) | 8 | 1 | 6 | 4 | 19 |
| Of Childbearing Potential | 0 | 0 | 0 | 0 | 0 |
| Post Hysterectomy | 1 | 1 | 0 | 2 | 4 |
| Surgically Sterilized | 0 | 2 | 0 | 0 | 2 |
| At least 1 year Post-Menopausal | 2 | 2 | 1 | 1 | 6 |
| Alcohol History(Participants) | Placebo | ORMD-0801 qd | ORMD-0801 Bid | ORMD-0801 Tid | Total |
|---|---|---|---|---|---|
| Never | 6 | 3 | 2 | 5 | 16 |
| Current | 5 | 3 | 4 | 2 | 14 |
| Former | 0 | 0 | 1 | 0 | 1 |
| Tobacco History(Participants) | Placebo | ORMD-0801 qd | ORMD-0801 Bid | ORMD-0801 Tid | Total |
|---|---|---|---|---|---|
| Never | 8 | 5 | 5 | 5 | 23 |
| Current | 1 | 0 | 0 | 1 | 2 |
| Former | 2 | 1 | 2 | 1 | 6 |
| Caffiene History(Participants) | Placebo | ORMD-0801 qd | ORMD-0801 Bid | ORMD-0801 Tid | Total |
|---|---|---|---|---|---|
| Never | 1 | 1 | 1 | 1 | 4 |
| Current | 10 | 5 | 6 | 5 | 26 |
| Former | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Oct 2016, a primary completion of Feb 2017 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2018, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ORMD-0801
Oramed, Ltd.